Progesterone Clinical Trials

13 recruitingLast updated: May 29, 2026

There are 13 actively recruiting progesterone clinical trials across 8 countries. Studies span Phase 2, Not Applicable, Phase 1, Phase 3. Top locations include Pittsburgh, Pennsylvania, United States, Houston, Texas, United States, Atlanta, Georgia, United States. Updated daily from ClinicalTrials.gov.


Progesterone Trials at a Glance

13 actively recruiting trials for progesterone are listed on ClinicalTrialsFinder across 6 cities in 8 countries. The largest study group is Phase 2 with 4 trials, with the heaviest enrollment activity in Pittsburgh, Houston, and Atlanta. Lead sponsors running progesterone studies include Xiaojun Chen, City of Hope Medical Center, and Calla Lily Clinical Care Ltd.

Browse progesterone trials by phase

Treatments under study

About Progesterone Clinical Trials

Looking for clinical trials for Progesterone? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Progesterone trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Progesterone clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 113 of 13 trials

Recruiting

Enhancing Skin Appearance and Quality of Life in Breast Cancer Survivors on Aromatase Inhibitor Therapy

Estrogen Receptor-Positive Breast CarcinomaAnatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8+4 more
Mayo Clinic35 enrolled1 locationNCT06401889
Recruiting
Phase 2

High Cannabidiol Plant Extract (BRC-001) to Improve Aromatase Inhibitor-Induced Arthralgia in Women With Breast Cancer

Estrogen Receptor-Positive Breast CarcinomaAnatomic Stage II Breast Cancer AJCC v8Anatomic Stage 0 Breast Cancer AJCC v8+5 more
City of Hope Medical Center36 enrolled1 locationNCT06538389
Recruiting
Phase 1

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

Triple-Negative Breast CancerGastric CancerOvarian Cancer+25 more
NiKang Therapeutics, Inc.150 enrolled19 locationsNCT06586957
Recruiting
Phase 1

First in Human Safety and Ease of Use Assessment of 400mg Progesterone Callavid in Women With Luteal Phase Insufficiency

Luteal Phase InsuffiencyProgesterone Delivery
Calla Lily Clinical Care Ltd20 enrolled1 locationNCT07136922
Recruiting
Not Applicable

S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8Prognostic Stage IV Breast Cancer AJCC v8HER2/Neu Negative+3 more
SWOG Cancer Research Network739 enrolled723 locationsNCT03723928
Recruiting
Not Applicable

Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy

Triple-Negative Breast CarcinomaHER2-Positive Breast CarcinomaInvasive Breast Carcinoma+9 more
M.D. Anderson Cancer Center120 enrolled8 locationsNCT02945579
Recruiting

Smartphone vs Manual Interpretation of Biomarkers for Ovulation and Luteal Phase Detection (SMOM Study)

body temperatureFertilityMenstrual Cycle+6 more
Bruyère Health Research Institute.30 enrolled1 locationNCT07248046
Recruiting
Phase 2Phase 3

GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients

ObesityEndometrial NeoplasmsAtypical Endometrial Hyperplasia+1 more
Xiaojun Chen29 enrolled2 locationsNCT06379113
Recruiting
Phase 2Phase 3

GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients

Endometrial NeoplasmsAtypical Endometrial HyperplasiaProgesterone Resistance
Xiaojun Chen80 enrolled2 locationsNCT05316935
Recruiting
Not Applicable

Role of Low Dose Injectable Progesterone in Triggering Ovulation

Low DoseProgesteroneTriggering Ovulation
The General Authority for Teaching Hospitals and Institutes120 enrolled1 locationNCT06928844
Recruiting
Phase 1

PRE-I-SPY Phase I/Ib Oncology Platform Program

Triple-Negative Breast CancerMetastatic Breast CancerHER2-low Breast Cancer+18 more
QuantumLeap Healthcare Collaborative124 enrolled7 locationsNCT05868226
Recruiting
Phase 2

Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer

Triple-Negative Breast CarcinomaRecurrent Breast CarcinomaStage IV Breast Cancer+4 more
Northwestern University100 enrolled1 locationNCT03213041
Recruiting

The influence of preovulatory and postovulatory progesterone on the outcome of the in vitro fertilization (IVF)

Fertility problems among female patients and IVF outcome in terms of high preovulatory and postovulatory progesterone
University Hospital Centre Zagreb, Department of Obstetrics and Gynaecology400 enrolled1 locationACTRN12615001315505